Skip to main content

. 1980 Aug 2;281(6236):353–354. doi: 10.1136/bmj.281.6236.353

Hydrallazine in hypertension: is there a safe dose?

R F Bing, G I Russell, H Thurston, J D Swales

PMCID: PMC1713534 PMID: 6968614

353

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

Perry H. M., Jr Late toxicity to hydralazine resembling systemic lupus erythematosus or rheumatoid arthritis. Am J Med. 1973 Jan;54(1):58–72. doi: 10.1016/0002-9343(73)90084-3. [DOI] [PubMed] [Google Scholar]
Perry H. M., Jr, Tan E. M., Carmody S., Sakamoto A. Relationship of acetyl transferase activity to antinuclear antibodies and toxic symptoms in hypertensive patients treated with hydralazine. J Lab Clin Med. 1970 Jul;76(1):114–125. [PubMed] [Google Scholar]
Schröder H. Simplified method for determining acetylator phenotype. Br Med J. 1972 Aug 26;3(5825):506–507. doi: 10.1136/bmj.3.5825.506. [DOI] [PMC free article] [PubMed] [Google Scholar]

ACTIONS

RESOURCES